the key to the US IF market is that the FDA acknowledges it is a good thing to have a few selected imported brands so to minimise concentration of suppliers and alleviate any future shock. Hopefully, this leads them to extend the November 2022 date and fastrack permanent access to these foreign companies.
this would be a game changer for A2 as it has accumulated significant US tax losses which could be offset against these future IF earnings.
the key to the US IF market is that the FDA acknowledges it is a...
-
- There are more pages in this discussion • 3,723 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add A2M (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.78 |
Change
-0.040(0.83%) |
Mkt cap ! $3.460B | |||
| Open | High | Low | Value | Volume |
| $4.80 | $4.87 | $4.73 | $16.45M | 3.420M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $4.75 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.78 | 4935 | 1 |
View Market Depth
| Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
| A2M (ASX) Chart |